Charité researchers present a new study on the use of stroke emergency mobile ambulance

Is prehospital stroke treatment associated with better outcomes?

Berlin, Germany (August 25, 2016) – When treating a patient with stroke, every minute counts. A specialized stroke ambulance (Stroke Emergency Mobile or STEMO) allows physicians to start specific treatment, such as thrombolysis, at scene. A recent study conducted by researchers from Charité – Universitätsmedizin Berlin investigated whether this earlier response time leads to an improved prognosis. Patients who received the appropriate treatment during transfer to the hospital were less likely to have a disability three months after their stroke than patients who received conventional treatment. Although the difference in surviving without any disability slightly failed to reach the predefined level of significance, other outcomes such as severe disability or death were also more favorable in the STEMO group. Results from this study have been published in the journal The Lancet Neurology*.

Approximately 90% of strokes are ischemic strokes, i.e. they are caused by a blood clot blocking an artery in the brain. Arterial blockages of this kind can be dissolved by thrombolytic therapy. However, approximately 10% of strokes are caused by bleeding inside the brain (hemorraghic stroke). As such bleedings would be unstoppable under thrombolytic therapy, it is essential to exclude cerebral bleedings before starting treatment. Physicians achieve this by using computed tomography (CT) for brain scanning, usually in hospital.

Led by Prof. Dr. Heinrich Audebert, clinical lead of the Department of Neurology at Campus Benjamin Franklin, the researchers studied whether early thrombolytic therapy influences the patient’s subsequent degree of disability. This was done by comparing the outcomes of patients who received thrombolysis after being transported to hospital in a conventional emergency vehicle and those patients who received thrombolysis already inside the STEMO. Patients from both groups had their degree of disability assessed three months after stroke.

"Our results suggest that earlier thrombolysis, delivered in STEMO already before hospital arrival, results in fewer disabilities that affect daily living, and in better survival rates," says the study’s first author, Dr. Alexander Kunz. He adds: "The earlier acute stroke treatment starts, the better the outcomes. Data from our study suggest that, wherever possible, treatment should commence prior to arrival at hospital." Early treatment of this type is made possible through specially-equipped mobile stroke treatment units, such as the STEMO, which is jointly operated by the Berlin Fire Department and the Center for Stroke Research Berlin. The ambulance, that is equipped with a CT scanner and a mini-laboratory, is staffed by a neurologist who is also trained in emergency medicine. A previous study by the Charité researchers had shown that patients treated in the STEMO received potentially life-saving thrombolysis on average by 25 minutes earlier compared to patients who were admitted by conventional ambulance and treated after hospital arrival.

  • *Kunz A, Ebinger M, Geisler F, Rozanski M, Waldschmidt C, Weber JE, Wendt M, Winter B, Zieschang K, Fiebach JB, Villringer K, Erdur H, Scheitz JF, Tütüncü S, Bollweg K, Grittner U, Kaczmarek S, Endres M, Nolte CH, Audebert HJ. Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study. Lancet Neurol 2016; 15: 1035-1043. doi: 10.1016/S1474-4422(16)30129-6.

Links


Charité – Universitätsmedizin Berlin , 25.08.2016 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…